Zoledronic acid in the treatment of Paget’s disease and other benign bone disorders

Abstract

Zoledronic acid is a potent bisphosphonate widely used to counteract cancer-related bone loss. Once-yearly or even less frequent doses may be an effective therapy for benign bone disorders and may also result in improved compliance and tolerability. Data from two Phase III clinical trials have demonstrated the efficacy and safety of zoledronic acid in the treatment of Paget’s disease of bone. Other studies have provided preliminary evidence for the utility of zoledronic acid in osteoporosis and other benign bone disorders. The major adverse effects associated with zoledronic acid infusions are transient flu-like symptoms. Ongoing clinical trials will provide key data on the ability of this agent to treat osteoporosis and prevent fractures in high-risk patients and on its long-term safety profile.

Keywords::

• bisphosphonate
• bone resorption
• clinical efficacy
• osteoporosis
• Paget’s disease
• prevention
• safety
• treatment
• zoledronic acid